title: Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway.
abstract: The use of adherent monolayer cultures have produced many insights into melanoma cell growth and differentiation, but often novel therapeutics demonstrated to act on these cells are not active in vivo. It is imperative that new methods of growing melanoma cells that reflect growth in vivo are investigated. To this end, a range of human melanoma cell lines passaged as adherent cultures or induced to form melanoma spheres (melanospheres) in stem cell media have been studied to compare cellular characteristics and protein expression. Melanoma spheres and tumours grown from cell lines as mouse xenografts had increased heterogeneity when compared with adherent cells and 3D-spheroids in agar (aggregates). Furthermore, cells within the melanoma spheres and mouse xenografts each displayed a high level of reciprocal BRN2 or MITF expression, which matched more closely the pattern seen in human melanoma tumours in situ, rather than the propensity for co-expression of these important melanocytic transcription factors seen in adherent cells and 3D-spheroids. Notably, when the levels of the BRN2 and MITF proteins were each independently repressed using siRNA treatment of adherent melanoma cells, members of the NOTCH pathway responded by decreasing or increasing expression, respectively. This links BRN2 as an activator, and conversely, MITF as a repressor of the NOTCH pathway in melanoma cells. Loss of the BRN2-MITF axis in antisense-ablated cell lines decreased the melanoma sphere-forming capability, cell adhesion during 3D-spheroid formation and invasion through a collagen matrix. Combined, this evidence suggests that the melanoma sphere-culture system induces subpopulations of cells that may more accurately portray the in vivo disease, than the growth as adherent melanoma cells.
authors.affiliation: Institute for Molecular Bioscience, Melanogenix Group, The University of Queensland, Brisbane, Queensland, Australia.
authors.forename: A E
authors.initials: AE
authors.lastname: Thurber
authors.forename: G
authors.initials: G
authors.lastname: Douglas
authors.forename: E C
authors.initials: EC
authors.lastname: Sturm
authors.forename: S E
authors.initials: SE
authors.lastname: Zabierowski
authors.forename: D J
authors.initials: DJ
authors.lastname: Smit
authors.forename: S N
authors.initials: SN
authors.lastname: Ramakrishnan
authors.forename: E
authors.initials: E
authors.lastname: Hacker
authors.forename: J H
authors.initials: JH
authors.lastname: Leonard
authors.forename: M
authors.initials: M
authors.lastname: Herlyn
authors.forename: R A
authors.initials: RA
authors.lastname: Sturm
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D018398:Homeodomain Proteins / Q000235:genetics*; D006801:Humans; D008545:Melanoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D051739:Microphthalmia-Associated Transcription Factor / Q000235:genetics*; D050809:POU Domain Factors / Q000235:genetics*; D051880:Receptors, Notch / Q000378:metabolism*; D014183:Transplantation, Heterologous
chemical_list: D018398:Homeodomain Proteins; C497234:MITF protein, human; D051739:Microphthalmia-Associated Transcription Factor; D050809:POU Domain Factors; D051880:Receptors, Notch; C085076:transcription factor Brn-2